The NeoPalAna study [77] is a phase II trial which evaluated anastrozole monotherapy vs. anastrozole + palbociclib in 50 patients with clinical stage II or III, ER+ HER2 negative breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.